Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Savella for Pain Processing in Fibromyalgia
NCT01173055Phase 4Completed
- Sponsor
- University of Michigan
- Start
- Jun 2010
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of milnacipran in fibromyalgia (FM) (2 arms), sponsored by University of Michigan. Primary endpoints: Pain Threshold at 9 weeks and Change in Pain Threshold From Baseline to End of Treatment at 6 weeks. Started Jun 2010; status: completed.
02
Drugs
milnacipran
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT01173055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01173055.